Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer.

Eleonora LaiNicole LisciaClelia DonisiStefano MarianiSimona ToluAndrea PrettaMara PersanoGiovanna PinnaFrancesca BalconiAnnagrazia PiredduValentino ImperaMarco DuboisMarco MigliariDario SpanuGiorgio SabaSilvia CameraFrancesca MusioPina ZiranuMarco PuzzoniLaura DemurtasValeria PuscedduManuela DettoriElena MassaFrancesco AtzoriMariele DessìGiorgio AstaraClelia MadedduMario Scartozzi

Published in: Cancers (2020)

Several molecular biomarkers have been identified for the tailored treatment of mCRC patients and multiple efforts are currently ongoing to increase the therapeutic options. In the era of precision medicine, molecular-biology-driven treatment is the key to impro patient selection and patient outcomes. Further research and large phase III trials are required to ameliorate the therapeutic management of these patients.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
metastatic colorectal cancer
randomized controlled trial
single molecule
combination therapy
case report
quality improvement
replacement therapy
phase ii